Novartis Acquires Avidity Biosciences for $12 Billion: RNA Therapeutics Pioneer Bolsters Neuroscience Pipeline
Novartis AG has struck a transformative deal to acquire Avidity Biosciences Inc. in a cash transaction valued at approximately $12 billion, marking one of the largest biotech buyouts of 2025 and strengthening the Swiss pharmaceutical giant’s position in neuromuscular disease […]










